The VPS13 family (VPS13A, VPS13B, VPS13C, VPS13D) constitutes a unique class of bridge-like lipid transfer proteins (LTPs) that span between organelles, creating contact sites where lipids can be directly transferred without vesicular intermediates. VPS13A (linked to chorea-acanthocytosis) and VPS13C (linked to autosomal recessive Parkinson's disease) represent particularly compelling therapeutic targets because they directly connect endoplasmic reticulum (ER) dynamics to mitochondrial health, lysosomal function, and neuronal survival — all core pillars of neurodegeneration. Genetic validation is strong: VPS13A loss-of-function causes adult-onset progressive movement disorder with neurodegeneration, and VPS13C mutations cause early-onset PD with rapid progression. This therapy proposes small-molecule modulators or gene therapy to restore VPS13-dependent lipid transport and organelle contact site function as a disease-modifying approach across multiple proteinopathies[1][2].
The VPS13 family operates at the intersection of several critical neurodegenerative pathways:
1. ER-Mitochondria Lipid Transfer and Calcium Homeostasis
VPS13 proteins create stable contact sites between the ER and mitochondria (mitochondria-associated membranes, MAMs). At these sites, they transfer phospholipids (phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol) from the ER to mitochondria — a process essential for mitochondrial membrane biogenesis, respiratory chain function, and calcium signaling[3]. VPS13A deficiency disrupts MAM integrity, causing:
2. VPS13A → Chorea-Acanthocytosis (ChAc)
ChAc is an autosomal recessive disorder caused by VPS13A mutations (primarily nonsense/truncating). It presents with:
The connection: VPS13A is essential for neuronal morphology maintenance (especially neurite length and branching), process formation, and synaptic terminal integrity. Loss of VPS13A causes:
3. VPS13C → Autosomal Recessive Parkinson's Disease
Loss-of-function mutations in VPS13C cause early-onset PD (median onset ~45 years) with:
VPS13C localizes to ER-lysosome contact sites where it mediates lipid transfer essential for lysosomal membrane composition and function. VPS13C deficiency causes:
4. VPS13D → Mitochondrial Dynamics and Stress Response
VPS13D interacts with peroxisomes and regulates mitochondrial metabolism. Its knockdown causes:
VPS13D is particularly important under metabolic stress conditions, suggesting it may be a resilience factor that could be therapeutically enhanced[7].
Cross-links to relevant mechanisms:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9/10 | VPS13 family as drug targets is underexplored; lipid transfer protein modulation is a first-in-class mechanism for neurodegeneration |
| Mechanistic Rationale | 9/10 | VPS13A causes ChAc (genetic), VPS13C causes PD (genetic), VPS13D regulates mitophagy; all three validated in human disease and animal models |
| Addresses Root Cause | 8/10 | Organelle contact site dysfunction underlies multiple downstream pathologies (mitochondrial failure, lysosomal impairment, ER stress) — true upstream convergence point |
| Delivery Feasibility | 6/10 | Gene therapy (AAV-VPS13A/C) is primary approach for loss-of-function; small-molecule contact site stabilizers are emerging but less mature |
| Safety Plausibility | 8/10 | Haploinsufficiency may be sufficient for therapeutic effect (VPS13A heterozygous carriers show no obvious disease); overexpression of native protein is lower risk than enzyme inhibition |
| Combinability | 9/10 | Combines with mitophagy enhancers (PINK1/Parkin), GCase activators (lyso ER function), and anti-aggregation approaches |
| Biomarker Availability | 7/10 | Mitochondrial morphology (imaging), lysosomal function assays, VPS13 protein levels in patient-derived neurons, NfL for tracking progression |
| De-risking Path | 7/10 | iPSC models from ChAc and VPS13C-PD patients available; VPS13A knockout mice recapitulate key phenotypes; clear readouts for target engagement |
| Multi-disease Potential | 9/10 | VPS13A covers ChAc and potentially HD; VPS13C covers PD and DLB; VPS13D has broad relevance to AD, PD, and ALS; lipid transport is universally important |
| Patient Impact | 8/10 | VPS13-linked diseases are severe and currently without disease-modifying options; targeting the root cause of a monogenic disease offers high impact |
| Total | 80/100 |
| Disease | Relevance | Rationale |
|---|---|---|
| Chorea-Acanthocytosis | Very High | Direct causative gene; VPS13A LOF is the disease mechanism[4:1] |
| Parkinson's Disease (VPS13C-linked) | Very High | VPS13C mutations cause autosomal recessive PD with early onset and rapid progression[6:1] |
| Huntington's Disease | Medium | Shared basal ganglia vulnerability; VPS13A dysfunction models show similar striatal degeneration patterns |
| Parkinson's Disease (sporadic) | Medium | VPS13C variants may be risk factors; VPS13D variants may influence mitochondrial resilience |
| Alzheimer's Disease | Medium | ER-mitochondria dysfunction is a hallmark of AD; VPS13D regulates mitochondrial metabolism relevant to neuronal bioenergetics[7:1] |
| Dementia with Lewy Bodies | Medium | Lysosomal dysfunction and α-synuclein aggregation — both downstream of VPS13C deficiency |
| ALS/FTD | Low-Medium | Mitochondrial dysfunction is central; VPS13D ortholog mutants cause neurodegeneration in flies |
Primary Goal: Validate VPS13A/C as therapeutic targets in patient-derived neurons
Ramrath N, et al. VPS13A and VPS13C are lipid transfer proteins at ER-organelle contact sites. EMBO Reports. 2023. ↩︎
Yesantharao P, et al. VPS13C links lysosomal and endoplasmic reticulum dynamics in human neurons. Journal of Cell Biology. 2021. ↩︎ ↩︎
Hung VH, et al. Mechanism of lipid transfer by the VPS13 family. Nature Structural and Molecular Biology. 2021. ↩︎
Schwandt A, et al. VPS13A mutations causing chorea-acanthocytosis lead to impaired mitophagy and mitochondrial dysfunction. Brain. 2023. ↩︎ ↩︎
Dawson TM, et al. The chorea-acanthocytosis protein VSP13A is a key regulator of cell morphology and organelle dynamics. Proceedings of the National Academy of Sciences. 2010. ↩︎
Lesage S, et al. VPS13C Parkinsonism: clinical, neuroimaging and genetic characterization. Brain. 2023. ↩︎ ↩︎
Kumar N, et al. VPS13D regulates cellular metabolism and mitochondrial function through interaction with peroxisomes. Nature Communications. 2022. ↩︎ ↩︎